The combination of antidepressant plus antipsychotic may improve clinical response rates in the treatment of depressive episodes associated with bipolar disorder as well as treatment resistant depression. Some studies suggest benefit also for the treatment of negative symptoms of schizophrenia.
Symbyax® combines olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor. It is indicated for the acute treatment of depressive episodes associated with bipolar disorder in adults and for the treatment of treatment resistant depression.
